Bruton's tyrosine kinase in systemic lupus erythematosus

Liao, Hsien Tzung; Tung, Hsiang-Yuen; Tsai, Chang‐Youh; Chiang, Bor‐Luen; Yu, Chia-Li

doi:10.1016/j.jbspin.2020.05.004

Cited by 4 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…BTK can promote the response of BCR to antigen binding and stimulation through CD40, Toll-like receptor (TLR), Fc receptor (Fcr) and chemokine receptor (CCR) activate the downstream NF-κB pathway, producing cytokines and antibodies, and mediating cell proliferation, differentiation, activation and immune function [ 12 ]. In SLE patients, increased BTK expression in peripheral blood was associated with lupus nephritis [ 13 , 14 ]. BTK protein was elevated in B cells of patients with primary Sjogren’s syndrome (PSjS) [ 15 ].…”

Section: Discussionmentioning

confidence: 99%

Changes in the BTK/NF-κB signaling pathway and related cytokines in different stages of neuromyelitis optica spectrum disorders

et al. 2022

View full text Add to dashboard Cite

Objective Neuromyelitis optica spectrum disorders (NMOSDs) are blindness-causing neuritis; their pathogenesis is still not fully elucidated. Although it has been determined that Bruton tyrosine kinase (BTK) and NF-κB are associated with NMOSD, the changes that occur in different periods remain unknown. The study aimed to demonstrate the changes in the BTK/NF-κB pathway and related chemokines in different stages of NMOSDs. Methods A total of 32 patients with NMOSD were selected as the experimental group, and 32 healthy volunteers were included in the control group. In this study, the BTK/NF-κB pathway and related chemokines in the cerebrospinal fluid and peripheral blood samples of patients with NMOSD were analyzed in the acute or remission phase. Results BTK, NF-κB, PI3K, IKK, CXCL2, and CXCL12 levels in the NMOSD group in the acute or remission phase were significantly higher than those in the control group (p < 0.05). Conclusion The BTK/NF-κB pathway plays a vital role in the progression of NMOSD pathology. Our results shed light on its important role as a therapeutic target for NMOSD.

show abstract

Section: Discussionmentioning

confidence: 99%

Changes in the BTK/NF-κB signaling pathway and related cytokines in different stages of neuromyelitis optica spectrum disorders

et al. 2022

View full text Add to dashboard Cite

show abstract

“…SLE is characterized by loss of immune tolerance and overproduction of autoantibodies against self-antigens, followed by the formation of immune complexes that contribute to inflammation and tissue damage in multiple organs [ 308 ]. An elevated expression and activation of BTK were observed in SLE patients, along with an activation of BCR and FcR signalings in B cells and myeloid cells [ 309 ]. These responses promoted cell activation and differentiation, culminating in enhanced production of autoreactive antibodies and inflammatory cytokines, including anti-DNA antibodies [ 296 , 310 ].…”

Section: Btk Inhibitors In Inflammatory Diseasesmentioning

confidence: 99%

BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies

Alu

Han

et al. 2022

J Hematol Oncol

View full text Add to dashboard Cite

Bruton’s tyrosine kinase (BTK) is an essential component of multiple signaling pathways that regulate B cell and myeloid cell proliferation, survival, and functions, making it a promising therapeutic target for various B cell malignancies and inflammatory diseases. Five small molecule inhibitors have shown remarkable efficacy and have been approved to treat different types of hematological cancers, including ibrutinib, acalabrutinib, zanubrutinib, tirabrutinib, and orelabrutinib. The first-in-class agent, ibrutinib, has created a new era of chemotherapy-free treatment of B cell malignancies. Ibrutinib is so popular and became the fourth top-selling cancer drug worldwide in 2021. To reduce the off-target effects and overcome the acquired resistance of ibrutinib, significant efforts have been made in developing highly selective second- and third-generation BTK inhibitors and various combination approaches. Over the past few years, BTK inhibitors have also been repurposed for the treatment of inflammatory diseases. Promising data have been obtained from preclinical and early-phase clinical studies. In this review, we summarized current progress in applying BTK inhibitors in the treatment of hematological malignancies and inflammatory disorders, highlighting available results from clinical studies.

show abstract

Bruton’s tyrosine kinase: A promising target for treating systemic lupus erythematosus

Ding,

Zhou,

Feng

et al. 2024

International Immunopharmacology

View full text Add to dashboard Cite

Bruton's tyrosine kinase in systemic lupus erythematosus

Cited by 4 publications

References 9 publications

Changes in the BTK/NF-κB signaling pathway and related cytokines in different stages of neuromyelitis optica spectrum disorders

Changes in the BTK/NF-κB signaling pathway and related cytokines in different stages of neuromyelitis optica spectrum disorders

BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies

Bruton’s tyrosine kinase: A promising target for treating systemic lupus erythematosus

Contact Info

Product

Resources

About